An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate an Pemetrexed Single Agent given as Neoadjuvant Treatment in Patients with Resectable Rectal Cancer
Read time: 1 mins
Last updated:13th Jan 2010
Evaluation of optimal dose of Methylenetetrahydrofolate (Modufolin) in combination with a fixed dose of Pemetrexed (Alimta) 500mg/m2 related to the safety margins as described.
|Study start date||2010-01-13|